NCT02498912View on ClinicalTrials.gov

Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2026

Conditions
Solid Tumors
Interventions
PROCEDURE

Production of Genetically-modified T cells

DRUG

Cyclophosphamide

DEVICE

IP Catheter Insertion

GENETIC

Infusion of 4H11-28z/fIL-12/EGFRt+ Genetically-modified T cells

Patients who do not have sufficient CAR T cells for the assigned dose cohort will be treated in the cohort for which cells are available.

DRUG

Fludarabine

fludarabine dose 25-30 mg/m2 x 3 days

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center, New York

All Listed Sponsors
collaborator

Stanford University

OTHER

collaborator

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER